Novartis pays $310 million upfront for inflammation specialist IFM

FAN Editor
FILE PHOTO: Swiss drugmaker Novartis' logo is seen in Stein
FILE PHOTO: Swiss drugmaker Novartis’ logo is seen at the company’s plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann/File Photo

April 1, 2019

ZURICH (Reuters) – Novartis on Monday said it had agreed to pay $310 million upfront, with the possibility for more later, for some assets of Boston-based inflammation specialist IFM Therapeutics as the Swiss drugmaker seeks to expand its immunology pipeline.

The deal for the IFM subsidiary IFM Tre could eventually reach nearly $1.6 billion, IFM said in a statement, should the portfolio of clinical and preclinical molecules meet milestones. IFM has one molecule, IFM-2427, in an early Phase 1 trial, as well as other less-developed assets.

(Reporting by John Miller, editing by John Revill)

Free America Network Articles

Leave a Reply

Next Post

Turkey's move to prop up the lira before elections hurt its credit standing: Moody's

Ahead of the weekend’s crucial elections, Turkey’s central bank used its reserves to prop up the lira, renewing questions on its independence, said Moody’s Ratings Agency which rated the country “credit negative” on Monday. Last week, Turkey’s central bank published data showing that its gold and foreign exchange reserves dropped […]